Savolitinib - AstraZeneca

Drug Profile

Savolitinib - AstraZeneca

Alternative Names: AZD-6094; HMP-504; HMPL-504; Volitinib

Latest Information Update: 19 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hutchison MediPharma
  • Developer AstraZeneca; Hutchison MediPharma; National Cancer Institute (USA); Samsung Medical Center
  • Class Antineoplastics; Imidazoles; Pyrazines; Pyrazoles; Pyridines; Small molecules; Triazines; Triazoles
  • Mechanism of Action Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Renal cell carcinoma
  • Phase II Adenocarcinoma; Lung cancer; Non-small cell lung cancer; Prostate cancer
  • Phase I Gastric cancer
  • No development reported Solid tumours

Most Recent Events

  • 02 Feb 2018 AstraZeneca announces intention to submit regulatory application for Renal cell carcinoma in USA and European Union in 2020
  • 28 Dec 2017 Canadian Cancer Trials Group in collaboration with Canadian Cancer Clinical Trials Network and BC Cancer Foundation plans the phase II Prostate Cancer Biomarker Enrichment and Treatment Selection (PC-BETS) study for Prostate cancer in USA (NCT03385655)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Gastric-cancer(Combination therapy, Late-stage disease, Second-line therapy or greater) in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top